Novogen Limited (KZIA) – What Are Analysts Saying About This Stock?

Shares of Novogen Limited (NASDAQ:KZIA) have received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $29.00.

A number of analysts recently weighed in on the company. Leerink Partners initiated coverage on Novogen in a report on Tuesday. They issued an “outperform” rating and a $30.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Novogen in a report on Thursday, September 10th. Finally, Canaccord Genuity Group began coverage on Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 target price on the stock.

Novogen Stock Performance

Shares of NASDAQ KZIA opened at $7.88 on Wednesday. The firm has a 50 day moving average price of $11.07 and a two-hundred day moving average price of $11.99. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40.

About Novogen

Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.